Cryptococcus is rare, but twice as likely with JAK inhibitors. Retrospective TriNetX analysis of RA pts (>30k/grp) starting JAKi vs TNFi; JAKi vs non-TNFi; & TNFi vs non-TNF. Crypto seen in <0.2% in all groups; but signif higher HR for JAKi (HR 2.2 & 2.15) https://t.co/1J4SjcqF8u

REVEAL study enrolled 418 early microscopic polyangiitis pts - High baseline (Pre-Rx) neutrophil-to-lymphocyte ratio (NLR > 10) was assoc w/ signif higer Dz activity (BVAS), alveolar hemorrhage, poor renal function, reduced survival & higher infection-related mortality (P = https://t.co/wYBOz00GGB

FDA has granted Fast Track designation to EG-501 (Evergreen), investigational Rx for cognitive impairment with neuropsychiatric systemic lupus erythematosus (NPSLE), following positive results from the phase 2 ClearMEMory study https://t.co/n9wO2wLLBk https://t.co/E0kL3j931Z

Biologic safety. Vasculitis mimics. What to do with seropositive arthralgia. RheumNow Live 2027 tackles the decisions you face in clinic. Jan. 30–31 | Onsite + virtual Registration NOW OPEN. Early Bird Pricing through 12/15/2026. https://t.co/zYYC2350tE https://t.co/mPI1o7sEcx

Treat-to-Target has Excellent 10-Year Outcomes in RA Most patients with RA whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission 10 years later, with only modest radiographic progression over that time, researchers said. https://t.co/sFI67Wo2fK

Monogenic Inflammatory Disorders Go Unrecognized Lancet Rheumatology published a large cohort analysis using a genome-first approach with whole-exome sequencing, finding a prevalence of 1 in 4026 (159/640092) for monogenic disorders, half with inflammatory features. Only one https://t.co/4v1PP41rii

Joint Disease in SLE Reconsidered A new Frontiers in Immunology review from Ong, Wincup and colleagues, shows that lupus arthropathy is not a single uniform entity and it is biologically under-studied and clinically mismeasured, Moreover, the biology of lupus arthritis may https://t.co/M5m6TMZr3x

RheumNow Live 2027 registration is NOW OPEN. GLP-1s in your clinic. CAR-T in lupus. Rheumatology experts vs. AI, with your vote. Jan. 30–31 | Onsite + virtual Early Bird Pricing through 12/15/2026. See the agenda. Register: https://t.co/zYYC2350tE https://t.co/QeSxDPlIpv

Using Global Burden of Disease study data, an economic evaluation of 204 countries & territories, osteoarthritis & Alzheimers/dementias had highest health burden, but largest economic losses observed for combinations involving osteoarthritis, particularly osteoarthritis and https://t.co/0JgRgJAWy7

150 #Gout pts (56 yrs old; 33wks F/U; 21% drank EtOH, 29% obese, 5% MASLD) on allopurinol followed w/ labs. 30y (20%) had incr AST/ALT (87% mild, none severe). Allopurinol was cont 18/10 without change in AST/ALT. Allopurinol was not the primary cause of LFT elevation https://t.co/nBCACpvr5W

The FDA is reviewing Sun Pharma’s tildrakizumab (Ilumya), an IL-23 inhibitor, for use in active psoriatic arthritis, with an October 29, 2026 action (PDUFA) date. Decisons to be based on PsA INSPIRE-1 and INSPIRE-2 Phase 3 Studies https://t.co/iDWhub0k91 https://t.co/j8wQLxNCdA

RHEUMATOLOGIST Survey Q: How do you assess cutaneous lupus activity or treatment responses? CLICK HERE> https://t.co/PZDVpkqR1q https://t.co/bAQ7qNqGIA

Tis the Season for Vaccination Vaccination is essential for all rheumatologic patients, but particularly for patients on glucocorticoids and immunosuppression who face increased risk from infectious diseases. https://t.co/hHx1okkwHD https://t.co/nzRa9pzQ1X

Novel Imaging of Skin Disease in Scleroderma An emerging technique called spatial frequency domain imaging (SFDI) proved its mettle for evaluating skin fibrosis in systemic sclerosis (SSc), also called scleroderma, in an early clinical study. https://t.co/vHmxD1cHRR https://t.co/BWW6Te9FFI

Impact of Myositis in Scleroderma Patients Systemic sclerosis (SSc) may have overlap features such as myositis. When present, myositis in SSc is associated with an increased risk of cardiac involvement and a shift in mortality away from ILD towards a greater cardiac risk. https://t.co/dsGOXvdEuK